Journal: Brain Communications

Article Title: Thalamocortical network neuromodulation for epilepsy

doi: 10.1093/braincomms/fcaf270

Figure Lengend Snippet: Outcomes related to seizure severity, life satisfaction and sleep quality. ( A ) Seizure frequency % change from baseline until the last follow-up. ( B ) Box whisker plots of chronic thalamocortical network neuromodulation outcomes; mean marked by ‘x’ and median by a horizontal line. Change in seizure severity, life satisfaction and quality of sleep were adjusted to a 100-point scale. No worsening from baseline noted. Two-sided Wilcoxon signed-rank test P -values: seizure/month 0.0156, seizure severity 0.0312, life satisfaction 0.0312 and quality of sleep 0.0625; Benjamini–Hochberg false discovery rate–adjusted q values: 0.0417, 0.0417, 0.0417 and 0.0625, respectively. Statistically significant results are indicated by ‘*’.

Article Snippet: Chronic thalamocortical neuromodulation was delivered using FDA-approved neuromodulation hardware (supplemental-permanent implantation hardware) in an off-label manner [IPG, Boston Scientific Vercise Genus DBS R32 (4 leads, 32 electrode contacts) or Medtronic Intellis (4 leads, 16 electrode contacts); Electrodes: Boston Scientific DB-2201-45 and DB-2202-45, Medtronic 3387, Medtronic 3391].

Techniques: Whisker Assay